肿瘤溶瘤病毒疗法（OVT）是一种有前途的疗法，利用自然或经过改造的病毒或选择性复制和杀死癌细胞的倾向。过去十年，（临床前）研究主要集中在腺病毒、单纯疱疹病毒和牛痘病毒为基础的载体的开发和测试上。这些研究已经确定了困扰该领域取得成功的障碍。在这里，我们提出了一套全面性选择标准或成功的肿瘤溶瘤病毒的理想特性，其中包括无病原性、低血清流行率、选择性（感染和复制）、转基因携带能力和基因组稳定性。我们采用这些要求来分析溶瘤病毒领域，并确定一个潜在的最佳物种用于平台开发——溶血性口炎病毒。版权所有 © 2023。Elsevier Inc.出版。

Oncolytic virus therapy (OVT) is a promising modality that leverages the propensity of natural or engineered viruses to selectively replicate in and kill cancer cells. Over the past decade, (pre)clinical studies have focused on the development and testing of adenovirus, herpes simplex virus, and vaccinia virus-based vectors. These studies have identified barriers to success confronting the field. Here, we propose a set of selection criteria or ideal properties of a successful oncolytic virus, which include lack of pathogenicity, low seroprevalence, selectivity (infection and replication), transgene carrying capacity, and genome stability. We use these requirements to analyze the oncolytic virus landscape, and then identify a potentially optimal species for platform development - vesicular stomatitis virus.Copyright © 2023. Published by Elsevier Inc.